scholarly journals Age Differences in Cancer Treatment Decision Making and Social Support

2016 ◽  
Vol 29 (2) ◽  
pp. 187-205 ◽  
Author(s):  
Jessica L. Krok-Schoen ◽  
Angela L. Palmer-Wackerly ◽  
Phokeng M. Dailey ◽  
Julianne C. Wojno ◽  
Janice L. Krieger
Keyword(s):  
Social Support ◽  
Older Adults ◽  
Decision Making ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Age Groups ◽  
Treatment Decision ◽  
Middle Aged ◽  
Treatment Decision Making ◽  
Adult Cancer Survivors

Objective: The aim of this study was to examine the decision-making (DM) styles of younger (18-39 years), middle-aged (40-59 years), and older (≥60 years) cancer survivors, the type and role of social support, and patient satisfaction with cancer treatment DM. Method: Adult cancer survivors ( N = 604) were surveyed using Qualtrics online software. Results: Older adults reported significantly lower influence of support on DM than younger adults. The most common DM style for the age groups was collaborative DM with their doctors. Younger age was a significant predictor of independent ( p < .05), collaborative with family ( p < .001), delegated to doctor ( p < .01), delegated to family ( p < .001), and demanding ( p < .001) DM styles. Discussion: Despite having lower received social support in cancer treatment DM, older adults were more satisfied with their DM than younger and middle-aged adults. Health care workers should be aware of different DM styles and influence of social networks to help facilitate optimal patient DM and satisfaction.

scholarly journals Lay Referral Patterns Involved in Cardiac Treatment Decision Making Among Middle-Aged and Older Adults

2003 ◽  
Vol 43 (4) ◽  
pp. 493-502 ◽  
Author(s):  
N. E. Schoenberg ◽  
C. H. Amey ◽  
E. P. Stoller ◽  
S. B. Muldoon
Keyword(s):  
Older Adults ◽  
Decision Making ◽  
Treatment Decision ◽  
Middle Aged ◽  
Referral Patterns ◽  
Treatment Decision Making

scholarly journals The Impact of Dementia on Cancer Treatment Decision-Making, Cancer Treatment, and Mortality: A Mixed Studies Review

2021 ◽  
Author(s):  
Yaelin Caba ◽  
Kavita Dharmarajan ◽  
Christina Gillezeau ◽  
Katherine A Ornstein ◽  
Madhu Mazumdar ◽  
...  
Keyword(s):  
Older Adults ◽  
Decision Making ◽  
Cancer Treatment ◽  
Treatment Guidelines ◽  
Current Knowledge ◽  
Treatment Decision ◽  
Treatment Decision Making ◽  
Mixed Studies Review ◽  
The Impact ◽  
To Receive

Abstract Dementia and cancer occur commonly in older adults. Yet, little is known about the effect of dementia on cancer treatment and outcomes in patients diagnosed with cancer, and no guidelines exist. We performed a mixed studies review to assess the current knowledge and gaps on the impact of dementia on cancer treatment decision-making, cancer treatment, and mortality. A search in PubMed, Medline, and PsycINFO identified 55 studies on older adults with a dementia diagnosis before a cancer diagnosis and/or comorbid cancer and dementia published in English from January 2004 to February 2020. We described variability using range in quantitative estimates, ie, odds ratios (ORs) and hazard ratios (HRs) when appropriate and performed narrative review of qualitative data. Patients with dementia were more likely to receive no curative treatment (including hospice or palliative care) (OR, HR, and RR range 0.40– 4.4, n = 8), while less likely to receive chemotherapy (OR and HR range 0.11–0.68, n = 8), radiation (OR range 0.24–0.56, n = 2), and surgery (OR range 0.30–1.3, n = 4). Older adults with cancer and dementia had higher mortality than those with cancer alone (HR and OR range 0.92–5.8, n = 33). Summarized findings from qualitative studies consistently revealed that clinicians, caregivers, and patients tended to prefer less aggressive care and gave higher priority to quality of life over life expectancy for those with dementia. Current practices in treatment-decision making for patients with both cancer and dementia are inconsistent. There is an urgent need for treatment guidelines for this growing patient population that considers patient and caregiver perspectives.

The Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients

2022 ◽  
Author(s):  
Larissa Elisabeth Hillebrand ◽  
Ulrike Söling ◽  
Norbert Marschner
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Metastatic Breast Cancer ◽  
Cancer Treatment ◽  
Patient Reported Outcomes ◽  
Metastatic Breast ◽  
Treatment Decision ◽  
Breast Cancer Patients ◽  
Treatment Decision Making ◽  
Patient Reported

Background: Breast cancer is still the most common malignancy in women worldwide. Once metastasized, breast cancer treatment primarily aims at reducing symptom burden, thereby trying to maintain and improve a patient´s quality of life (QoL), delaying disease progression, and prolonging survival. Curing the disease is not possible in the palliative setting. To better understand metastatic breast cancer patients, their symptoms and wishes, which are important for treatment-decision making and outcome, patient-reported outcomes (PROs) are of great importance, giving an impression of what really matters to and concerns a patient. Summary: Many advances have been made to implicate PROs in clinical trials, non-interventional studies, registries, and clinical routine care of metastatic breast cancer. For example, large phase III trials like PALOMA-3 (NCT01942135), MONALEESA-7 (NCT02278120), HER2CLIMB (NCT02614794), and KEYNOTE-119 (NCT02555657) trials implemented PROs in their trial design to assess the QoL of their trial patients. Also, non-interventional studies on metastatic breast cancer, like e.g., the NABUCCO study (IOM-02240), and prospective non-interventional, multicenter registries e.g., the tumor registry breast cancer (NCT01351584) or the breast cancer registry platform OPAL (NCT03417115), have implemented PROs to assess QoL during the anti-cancer treatment periods of the patients. Key Message: Using PROs in metastatic breast cancer can support shared treatment-decision making and management of symptoms, eventually leading to an improvement in QoL. Progressively, regulatory authorities take PROs into consideration for the approval of new drugs. Hence, the implication of PROs in cancer treatment, and especially in MBC, is of significant value.

scholarly journals Perceived importance of affective forecasting in cancer treatment decision making

2020 ◽  
Vol 38 (6) ◽  
pp. 687-701
Author(s):  
Laura M. Perry ◽  
Michael Hoerger ◽  
Brittany D. Korotkin ◽  
Paul R. Duberstein
Keyword(s):  
Decision Making ◽  
Cancer Treatment ◽  
Treatment Decision ◽  
Affective Forecasting ◽  
Treatment Decision Making ◽  
Perceived Importance
Sign in / Sign up

Export Citation Format

Share Document